Year-End in Early Phase – What We’ve Learned, What’s Next
Reflecting on Our Milestones 2025 has been a landmark year for our early-phase research team. From first-in-human (FIH) studies to specialized trials in hepatic and renal impairment, and even Human Abuse Liability (HAL) assessments, we’ve advanced science in ways that bring new therapies closer to patients who need them most. These studies are the foundation …